Esperion Therapeutics (ESPR)
(Delayed Data from NSDQ)
$1.99 USD
-0.14 (-6.57%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $1.99 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth F Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ESPR 1.99 -0.14(-6.57%)
Will ESPR be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ESPR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ESPR
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
ESPR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is Esperion Therapeutics (ESPR) Up 2% Since Last Earnings Report?
Zacks Industry Outlook Highlights United Therapeutics, Esperion Therapeutics., Heron Therapeutics, Lyra Therapeutics and Aldeyra Therapeutics
5 Small Drug Stocks to Buy From a Rebounding Industry
Other News for ESPR
Tourlite Capital Q1 2024 Investor Letter
Esperion to Report First Quarter 2024 Financial Results on May 7
Applied Digital Reports Downbeat Results, Joins Nurix Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Understanding Serge Belanger’s Buy Rating for Esperion (ESPR): A Critical Analysis